Bioequivalence of mirabegron 50 mg extended release Tablet [Design Issues]

posted by Ibrahim Komeil – Egypt, 2021-02-20 11:36 (57 d 19:59 ago) – Posting: # 22218
Views: 562

Dear All
I had performed a 2X2 crossover study between test and reference product of mirabegron 50 mg under fasting conditions where 34 volunteers were completed the study.

Knowing that I couldn't find an accurate data for intrasubject variability of Mirabegnon. The results showed a very high unexpected intra-subject variability as following:
Cmax: 73.8451%, AUCt: 67.6524%
I calculated study power too and it results as following:
Cmax: 38.45% and AUCt: 42.38%

Therefore, a sequential two stage study won't be applicable in that condition. My question is: If i repeat the aforementioned study again, shall i follow a partial replicated cross over design or full replicated cross over design?

My second: Shall i follow RASBE or unscaled BE limits ?

Thanks in advance

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,510 registered users;
online 10 (0 registered, 10 guests [including 4 identified bots]).
Forum time: Monday 08:36 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5